The estimated Net Worth of James B Frakes is at least 392 千$ dollars as of 31 October 2018. Mr Frakes owns over 1,532 units of Aethlon Medical Inc stock worth over 6,740$ and over the last 20 years he sold AEMD stock worth over 0$. In addition, he makes 385,000$ as CFO、 Sr. VP of Fin. & Sec. at Aethlon Medical Inc.
Mr has made over 8 trades of the Aethlon Medical Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 1,532 units of AEMD stock worth 1,593$ on 31 October 2018.
The largest trade he's ever made was exercising 7,338 units of Aethlon Medical Inc stock on 7 February 2017 worth over 31,407$. On average, Mr trades about 1,117 units every 39 days since 2004. As of 31 October 2018 he still owns at least 17,877 units of Aethlon Medical Inc stock.
You can see the complete history of Mr Frakes stock trades at the bottom of the page.
James B. Frakes M.B.A. is the CFO, Sr. VP of Fin. & Sec. at Aethlon Medical Inc.
As the CFO、 Sr. VP of Fin. & Sec. of Aethlon Medical Inc, the total compensation of Mr A at Aethlon Medical Inc is 385,000$. There are 2 executives at Aethlon Medical Inc getting paid more, with Steven P. Larosa M.D. having the highest compensation of 513,800$.
Mr A is 64, he's been the CFO、 Sr. VP of Fin. & Sec. of Aethlon Medical Inc since . There are 4 older and 5 younger executives at Aethlon Medical Inc. The oldest executive at Aethlon Medical Inc is Edward Broenniman, 84, who is the Chairman of the Board.
James's mailing address filed with the SEC is 11555 SORRENTO VALLEY ROAD, SUITE 203, , SAN DIEGO, CA, 92121.
Over the last 11 years, insiders at Aethlon Medical Inc have traded over 56,658$ worth of Aethlon Medical Inc stock. The most active insiders traders include James A Joyce、Angela Rossetti、Chetan Shah. On average, Aethlon Medical Inc executives and independent directors trade stock every 56 days with the average trade being worth of 4,427$. The most recent stock trade was executed by Chetan Shah on 17 December 2020, trading 26,852 units of AEMD stock currently worth 56,658$.
the aethlon medical (nasdaq:aemd) mission is to create innovative devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. our aethlon adapt™ platform provides the technology foundation for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. the aethlon adapt™ product pipeline includes the hemopurifier®, a first-in-class medical device with broad-spectrum capabilities against exosomes that contribute to the progression of cancer and infectious viral pathogens such as hiv and hepatitis c.
Aethlon Medical Inc executives and other stock owners filed with the SEC include: